August 15, 2022
With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural-killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for prognosticating patients.
Read MoreAugust 15, 2022
PINK1-Parkin mediated mitophagy, a selective form of autophagy, represents one of the most important mechanisms in mitochondrial quality control (MQC) via the clearance of damaged mitochondria.
Read MoreAugust 10, 2022
SETDB1 is a key regulator of lineage-specific genes and endogenous retroviral elements (ERVs) through its deposition of repressive H3K9me3 mark.
Read MoreAugust 10, 2022
CSI Singapore would like to extend its heartiest congratulations to the graduates of the PhD Graduate Program in Cancer Biology!
Read MoreAugust 5, 2022
According to GLOBOCAN, gastric cancer (GC) is a significant cause of cancer mortality worldwide, with over 700,000 deaths attributable to it annually. Mesenchymal-subtype gastric cancer (Mes-GC) is a particularly aggressive subtype associated with poor clinical prognosis and chemoresistance. However, few effective treatment options are currently available. Existing regimens consist of “one-size-fits-all” approaches such as surgery […]
Read MoreJuly 25, 2022
The peritoneum is a common site of metastasis in advanced gastric cancer (GC). Diagnostic laparoscopy is now routinely performed as part of disease staging, leading to an earlier diagnosis of synchronous peritoneal metastasis (PM).
Read MoreJuly 25, 2022
Bioorthogonal catalysis (BC) generates chemical reactions not present in normal physiology for the purpose of disease treatment. Because BC catalytically produces the desired therapy only at the site of disease, it holds the promise of site-specific treatment with little or no systemic exposure or side effects.
Read MoreJuly 22, 2022
Transcriptional reactivation of hTERT is the limiting step in tumorigenesis. While mutations in hTERT promoter present in 19% of cancers are recognized as key drivers of hTERT reactivation, mechanisms by which wildtype hTERT (WT-hTERT) promoter is reactivated, in majority of human cancers, remain unknown.
Read MoreJuly 7, 2022
Most mammalian genes generate messenger RNAs (mRNAs) that consist of central protein-coding regions flanked by variable untranslated regions (UTRs). These UTRs, while not directly involved in protein production, nevertheless harbour many regulatory sequences and structures, and play important roles in post-transcriptional regulation, ensuring correct gene expression and function. Changes to these UTRs can be pathogenic, […]
Read MoreJune 14, 2022
Held in Honolulu, Hawaii between May 8 – 13, Ms. Xu Jingru presented at the NM05 Symposium, which focuses on discussions relating to the recent advances of nanodiamond in quantum sensing, diagnostic, biomedical and other novel applications.
Read MoreJune 13, 2022
Despite approvals of several therapeutics to treat advanced HCC in the past few years, the impact of anti-angiogenic treatment on HCC patient overall survival remains limited. This suggests there may be alternative, perfusion-independent roles of endothelial cells that support tumor progression.
Read MoreJune 13, 2022
Mutations in the DNA mismatch repair gene MSH2 are causative of microsatellite instability (MSI) in multiple cancers. Here, we discovered that besides its well-established role in DNA repair, MSH2 exerts a novel epigenomic function in gastric cancer (GC).
Read MoreJune 13, 2022
Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated.
Read MoreMay 27, 2022
Utilising a novel zebrafish cancer model, A/Prof. Takaomi Sanda and his team have been able to study the mechanism of cancer and elucidate tissue-specific oncogenicity. One such breakthrough would be the analysis of the oncogenicity of IRF4, an oncogene that is specifically expressed and regulates gene transcription in several types of mature lymphomas.
Read MoreMay 5, 2022
Congratulations to A/Prof. Edward Kai-Hua Chow and Dr. Bee Hui Liu, who have recently won awards at the Asian Fund for Cancer Research’s (AFCR) 2021 BRACE Award Venture Competition, a first-of-its-kind program for early-stage oncology technology companies focused on Asian-prevalent cancers.
Read MoreMay 5, 2022
RET is an estrogen response gene with preclinical studies demonstrating cross talk between RET and estrogen receptor (ER) pathways. We investigate the role of lenvatinib, a multi-kinase inhibitor with potent activity against RET, in patients with metastatic breast cancer.
Read MoreMay 5, 2022
Polycomb Repressive Complex 2 (PRC2) is an epigenetic regulator required for gene silencing during development. Although PRC2 is a well-established RNA-binding complex, the biological function of PRC2-RNA interaction has been controversial. Here, we study the gene-regulatory role of the inhibitory PRC2-RNA interactions. We report a nuclear long non-coding RNA, LEVER, which mapped 236 kb upstream of the ?-globin cluster as confirmed by Nanopore sequencing.
Read MoreMay 5, 2022
The dynamic regulation of alternative splicing requires coordinated participation of multiple RNA binding proteins (RBPs). Aberrant splicing caused by dysregulation of splicing regulatory RBPs is implicated in numerous cancers. Here, we reveal a frequently overexpressed cancer-associated protein, DAP3, as a splicing regulatory RBP in cancer.
Read MoreMay 4, 2022
In a novel step forward, A/Prof. Polly Chen and her team embarked on a study to better understand the role of crosstalk between RNA editing machinery (ADAR proteins) and circRNA biogenesis machinery in cancer. Findings from this interesting study will provide new insights that can contribute to the development of effective therapeutic approaches utilizing ADARs-regulated circRNAs, given their high stability and diverse functions.
Read MoreApril 6, 2022
Inhibitors of the mitotic kinase PLK1 yield objective responses in a subset of refractory cancers. However, PLK1 overexpression in cancer does not correlate with drug sensitivity, and the clinical development of PLK1 inhibitors has been hampered by the lack of patient selection marker. Using a high-throughput chemical screen, we discovered that cells deficient for the tumor suppressor ARID1A are highly sensitive to PLK1 inhibition.
Read More
Cancer Science Institute of Singapore
Centre for Translational Medicine
14 Medical Drive, #12-01,
Singapore 117599